Aussie Research Leads To Possible Treatment For TB
This article was originally published in PharmAsia News
Executive SummaryAustralian researchers say they have identified a basis for tuberculosis that could lead to the first new drug treatment in half a century. A research team at the Centenary Institute said a protein key to TB's survival has been identified, leading to a way to develop a drug to block it. TB is not a common threat in Australia, but it is in nearby island. The head of the research team said its discovery could lead to development of a drug that kills the responsible bacteria even as it lies dormant in the lungs. (Click here for more
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.